UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Fifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancer

JAMA internal medicine, 2014-09, Vol.174 (9), p.1460

2014

Volltextzugriff (PDF)

A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma

Pediatric blood & cancer, 2016-10, Vol.63 (10), p.1761-1770

2016

Volltextzugriff (PDF)

Outcomes of localized prostate cancer following conservative management

JAMA : the journal of the American Medical Association, 2009-09, Vol.302 (11), p.1202

2009

Volltextzugriff (PDF)

Population-based study of long-term survival in patients with clinically localised prostate cancer

The Lancet (British edition), 1997-03, Vol.349 (9056), p.906-910

1997

Volltextzugriff (PDF)

Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b study

Journal of the American Academy of Dermatology, 2024-07, Vol.91 (1), p.91-99

2024

Volltextzugriff (PDF)

Survival following primary androgen deprivation therapy among men with localized prostate cancer

JAMA : the journal of the American Medical Association, 2008-07, Vol.300 (2), p.173

2008

Volltextzugriff (PDF)

Fifteen-year Outcomes Following Conservative Management Among Men Aged 65 Years or Older with Localized Prostate Cancer

European urology, 2015-11, Vol.68 (5), p.805-811

2015

Volltextzugriff (PDF)

A randomized, phase II study of the anti‐insulin‐like growth factor receptor type 1 (IGF‐1R) monoclonal antibody robatumumab (SCH 717454) in patients with advanced colorectal cancer

Cancer medicine (Malden, MA), 2014-08, Vol.3 (4), p.988-997

2014

Volltextzugriff (PDF)

A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies

Journal of translational medicine, 2013-10, Vol.11 (1), p.259-259

2013

Volltextzugriff (PDF)

Response to: “Interleukin-23 Blockade Is Not Effective in Axial Spondyloarthritis”

Journal of clinical rheumatology, 2024-03, Vol.30 (2), p.e73-e73

2024

Volltextzugriff (PDF)

Intravenous pegylated liposomal prednisolone outperforms intramuscular methylprednisolone in treating rheumatoid arthritis flares: A randomized controlled clinical trial

Journal of controlled release, 2022-01, Vol.341, p.548-554

2022

Volltextzugriff (PDF)

A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study of Tildrakizumab Efficacy and Safety in Patients With Active Ankylosing Spondylitis

Journal of clinical rheumatology, 2023-08, Vol.29 (5), p.223-229

2023

Volltextzugriff (PDF)

Plasma and cerebrospinal fluid pharmacokinetics of vodobatinib, a neuroprotective c-Abl tyrosine kinase inhibitor for the treatment of Parkinson's disease

Parkinsonism & related disorders, 2023-03, Vol.108, p.105281-105281, Article 105281

2023

Volltextzugriff (PDF)

Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast Cancer

Clinical breast cancer, 2014-06, Vol.14 (3), p.169-176

2014

Volltextzugriff (PDF)

Prostate-specific antigen screening in elderly men

JNCI : Journal of the National Cancer Institute, 2003-12, Vol.95 (23), p.1792-1797

2003

Volltextzugriff (PDF)

Peer review of a clinical trial protocol: Practical tips for regulatory medical writers, clinicians, and clinical scientists

Medical writing (Leeds), 2023-03, Vol.32 (1), p.20-27

2023

Volltextzugriff (PDF)

Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2014-02, Vol.83 (2), p.219-223

2014

Volltextzugriff (PDF)

Understanding and Appreciating Overdiagnosis in the PSA Era

JNCI : Journal of the National Cancer Institute, 2002-07, Vol.94 (13), p.958-960

2002

Volltextzugriff (PDF)

Preclinical and Clinical Pharmacodynamic Assessment of L-778,123, a Dual Inhibitor of Farnesyl:Protein Transferase and Geranylgeranyl:Protein Transferase Type-I

Molecular cancer therapeutics, 2002-07, Vol.1 (9), p.747-758

2002

Volltextzugriff (PDF)

A Phase I and Pharmacological Study of the Farnesyl Protein Transferase Inhibitor L-778,123 in Patients with Solid Malignancies

Clinical cancer research, 2001-12, Vol.7 (12), p.3894-3903

2001

Volltextzugriff (PDF)

Characterization of a Novel Prostate-Specific Antigen–Activated Peptide-Doxorubicin Conjugate in Patients With Prostate Cancer

Journal of clinical oncology, 2002-04, Vol.20 (7), p.1874-1879

2002

Volltextzugriff (PDF)

The science and art of prostate cancer screening

JNCI : Journal of the National Cancer Institute, 2011-03, Vol.103 (6), p.450-451

2011

Volltextzugriff (PDF)

CHANGING PATTERNS IN COMPETING CAUSES OF DEATH IN MEN WITH PROSTATE CANCER: A POPULATION BASED STUDY

The Journal of urology, 2004-06, Vol.171 (6), p.2285-2290

2004

Volltextzugriff (PDF)

Does Primary Androgen-Deprivation Therapy Delay the Receipt of Secondary Cancer Therapy for Localized Prostate Cancer?

European urology, 2012-12, Vol.62 (6), p.966-972

2012

Volltextzugriff (PDF)

Population-Based Study of Relationships Between Hospital Volume of Prostatectomies,Patient Outcomes, and Length of Hospital Stay

JNCI : Journal of the National Cancer Institute, 1999-11, Vol.91 (22), p.1950-1956

1999

Volltextzugriff (PDF)

1 – 25 von 71

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(71)
Mit Volltextzugriff
(49)

Publikationsform

Artikel
(71)

Sprache

Englisch
(71)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Fifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancer

A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma

Outcomes of localized prostate cancer following conservative management

Population-based study of long-term survival in patients with clinically localised prostate cancer

Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b study

Survival following primary androgen deprivation therapy among men with localized prostate cancer

Fifteen-year Outcomes Following Conservative Management Among Men Aged 65 Years or Older with Localized Prostate Cancer

A randomized, phase II study of the anti‐insulin‐like growth factor receptor type 1 (IGF‐1R) monoclonal antibody robatumumab (SCH 717454) in patients with advanced colorectal cancer

A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies

Response to: “Interleukin-23 Blockade Is Not Effective in Axial Spondyloarthritis”

Intravenous pegylated liposomal prednisolone outperforms intramuscular methylprednisolone in treating rheumatoid arthritis flares: A randomized controlled clinical trial

A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study of Tildrakizumab Efficacy and Safety in Patients With Active Ankylosing Spondylitis

Plasma and cerebrospinal fluid pharmacokinetics of vodobatinib, a neuroprotective c-Abl tyrosine kinase inhibitor for the treatment of Parkinson's disease

Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast Cancer

Prostate-specific antigen screening in elderly men

Peer review of a clinical trial protocol: Practical tips for regulatory medical writers, clinicians, and clinical scientists

Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer

Understanding and Appreciating Overdiagnosis in the PSA Era

Preclinical and Clinical Pharmacodynamic Assessment of L-778,123, a Dual Inhibitor of Farnesyl:Protein Transferase and Geranylgeranyl:Protein Transferase Type-I

A Phase I and Pharmacological Study of the Farnesyl Protein Transferase Inhibitor L-778,123 in Patients with Solid Malignancies

Characterization of a Novel Prostate-Specific Antigen–Activated Peptide-Doxorubicin Conjugate in Patients With Prostate Cancer

The science and art of prostate cancer screening

CHANGING PATTERNS IN COMPETING CAUSES OF DEATH IN MEN WITH PROSTATE CANCER: A POPULATION BASED STUDY

Does Primary Androgen-Deprivation Therapy Delay the Receipt of Secondary Cancer Therapy for Localized Prostate Cancer?

Population-Based Study of Relationships Between Hospital Volume of Prostatectomies,Patient Outcomes, and Length of Hospital Stay

Suchergebnisse filtern